Focused On-demand Library for Regulator of G-protein signaling 9

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
O75916

UPID:
RGS9_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O75916; A8K3C0; O75573; Q696R2; Q8TD64; Q8TD65; Q9HC32; Q9HC33

BACKGROUND:
The protein Regulator of G-protein signaling 9 (RGS9) is essential for the recovery phase of visual transduction, ensuring the rapid termination of the phototransduction cascade. It achieves this by increasing the GTPase activity of G protein alpha subunits, a key step in the visual signal processing.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in phototransduction, RGS9's dysfunction is associated with Prolonged electroretinal response suppression 1, a childhood-onset ocular disorder. Targeting RGS9 could offer a therapeutic avenue for managing this visual impairment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 865 of 8789